Dapoxetine hydrochloride (CAS No 2699607-47-9) is a selective serotonin reuptake inhibitor (SSRI) primarily researched for its potential applications in the treatment of premature ejaculation Originating from the development of antidepressants its mechanism of action involves the inhibition of the serotonin transporter leading to increased serotonin levels in synaptic clefts and modulation of ejaculatory latency The compound exhibits activity in the nanomolar to low micromolar range in vitro indicating potent efficacy at minimal concentrations Commonly employed in neuronal cell models animal studies and drug screening assays Dapoxetine hydrochloride plays a vital role in elucidating serotonin pathways and testing therapeutic strategies Experimental concentrations typically depend on the specific research design ensuring tailored approaches to the investigation of its pharmacological effects and potential clinical applications